STOCK TITAN

Processa Pharmaceuticals (PCSA) awards 8,450 RSUs and reports option, stock holdings

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Processa Pharmaceuticals, Inc. officer Patrick Lin received a grant of 8,450 Restricted Stock Units on 2026-07-26. Each RSU equals one share of common stock, vesting upon grant but distributed only at the earlier of termination, six months after grant, a change of control, or death. Following this award, he holds 11,389 RSUs, stock options over 8,160 shares at an exercise price of $4.9600 that vest over three years, and common stock holdings of 13,113 shares directly plus 1,740 shares indirectly through the Lin Family Trust. These amounts reflect a 1-for-25 reverse stock split effective December 17, 2025, and were not reported as made under a Rule 10b5-1 trading plan.

Positive

  • None.

Negative

  • None.
Insider Lin Patrick
Role Chief Business - Strategy Off
Type Security Shares Price Value
Grant/Award Restricted Stock Units F1, F3 8,450 $0.00 $0.00
holding Stock Options (Right to Buy) F2, F3 -- -- --
holding Common Stock -- -- --
holding Common Stock -- -- --
Holdings After Transaction: Restricted Stock Units — 11,389 shares (Direct); Stock Options (Right to Buy) — 8,160 shares (Direct); Common Stock — 13,113 shares (Direct); Common Stock — 1,740 shares (Indirect, Lin Family Trust Feb 4, 2024)
Footnotes (3)
  1. F1. Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock. These RSUs vested upon grant, but will not be distributed until the earlier of: (i) their termination; (ii) six month anniversary of the grant date; (iii) change of control; or (iv) their death.
  2. F2. Stock options vest one-third on the first anniversary date of the grant, with the remaining options vesting ratably over the subsequent two years.
  3. F3. Reflects the 1-for-25 reverse stock split effected by the Issuer on December 17, 2025.
RSUs granted 8450.0000 units Restricted Stock Units granted to Patrick Lin on 2026-07-26
RSU balance after grant 11389.0000 units Total Restricted Stock Units held by Patrick Lin after the award
Stock options underlying shares 8160.0000 shares Underlying common shares for options held directly by Patrick Lin
Option exercise price 4.9600 Exercise price per share for Patrick Lin’s stock options
Direct common stock holdings 13113.0000 shares Common stock held directly by Patrick Lin
Indirect common stock holdings 1740.0000 shares Common stock held indirectly via Lin Family Trust Feb 4, 2024
Reverse stock split ratio 1-for-25 Reverse stock split effective December 17, 2025
Restricted Stock Units financial
"Each Restricted Stock Unit represents a contingent right to receive one share"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Stock Options (Right to Buy) financial
"Stock Options (Right to Buy) with an exercise price of 4.9600"
1-for-25 reverse stock split financial
"Reflects the 1-for-25 reverse stock split effected by the Issuer"
change of control financial
"distributed until the earlier of termination, six months, change of control, or death"
A change of control occurs when the ownership or management of a company shifts significantly, such as through a sale, merger, or acquisition, resulting in new leadership or ownership structure. This change can impact the company's direction and decision-making, which is important for investors because it may affect the company's stability, strategy, and future prospects.
Rule 10b5-1 trading plan financial
"Transactions were not reported as made under a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What did Processa Pharmaceuticals (PCSA) report about Patrick Lin’s new equity award?

Patrick Lin received 8,450 Restricted Stock Units (RSUs) on 2026-07-26. Each RSU equals one share of common stock, vests immediately upon grant, and will be distributed only upon termination, six months after grant, a change of control, or death.

How do the new RSUs for Processa (PCSA) executive Patrick Lin vest and pay out?

The 8,450 RSUs granted to Patrick Lin vested upon grant but defer distribution. Shares will be delivered at the earlier of termination, six months after the grant date, a change of control, or his death, according to the award terms.

What stock option position does Patrick Lin hold at Processa Pharmaceuticals (PCSA)?

Patrick Lin holds stock options over 8,160 underlying common shares at an exercise price of $4.9600. These options vest one-third on the first anniversary of the grant date, with the remaining two-thirds vesting ratably over the following two years.

How many Processa Pharmaceuticals (PCSA) shares does Patrick Lin own directly and indirectly?

Patrick Lin holds 13,113 shares of Processa common stock directly and 1,740 shares indirectly through the Lin Family Trust Feb 4, 2024. These ownership figures are reported as of 2026-07-26 and reflect a reverse stock split.

How did Processa’s 1-for-25 reverse stock split affect Patrick Lin’s reported holdings in PCSA?

All reported equity numbers, including 11,389 RSUs and options over 8,160 shares, reflect a 1-for-25 reverse stock split that was effective on December 17, 2025. The split adjusted prior share and unit counts proportionally.

Were Patrick Lin’s reported PCSA equity transactions made under a Rule 10b5-1 plan?

The filing indicates the transactions were not made under a Rule 10b5-1 trading plan. The document-level checkbox for Rule 10b5-1 arrangements is explicitly unchecked, suggesting no pre-arranged trading plan covered these reported equity awards and holdings.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Lin Patrick

(Last)(First)(Middle)
C/O PROCESSA PHARMACEUTICALS, INC.
601 21ST STREET SUITE 300

(Street)
VERO BEACH FLORIDA 32960

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Processa Pharmaceuticals, Inc. [ PCSA ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Business - Strategy Off
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/26/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock13,113D
Common Stock1,740ILin Family Trust Feb 4, 2024
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Units$007/26/2026A8,450(1) (1) (1)Common Stock8,450$011,389(3)D
Stock Options (Right to Buy)$4.96 (2) (2)Common Stock8,1608,160(3)D
Explanation of Responses:
1. Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock. These RSUs vested upon grant, but will not be distributed until the earlier of: (i) their termination; (ii) six month anniversary of the grant date; (iii) change of control; or (iv) their death.
2. Stock options vest one-third on the first anniversary date of the grant, with the remaining options vesting ratably over the subsequent two years.
3. Reflects the 1-for-25 reverse stock split effected by the Issuer on December 17, 2025.
/s/ Patrick Lin by John J. Wolfel, as Attorney-in-Fact07/28/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)